Accessibility Menu
Janux Therapeutics logo

Janux Therapeutics(NASDAQ) JANX

Current Price$16.29
Market Cap$978.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-36%
5 Year-44%
1 Year-39%
1 Month+13%
Janux Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 16.052026-07-20
Janux Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.56%USD 16.142026-07-13
1 month+12.87%USD 14.222026-06-18
3 month+3.82%USD 15.462026-04-21
Year to date+16.3%USD 13.802025-12-31
1 year-39.2%USD 26.402025-07-18
3 year+25.49%USD 12.792023-07-21
5 year-44.04%USD 28.682021-07-21
Since inception-36.18%USD 25.152021-06-11

Janux Therapeutics Financials at a Glance

Market Cap

$978.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$21.61M

Net Income (TTM)

-$114.48M

EPS (TTM)

-$1.84

P/E Ratio

-8.71

Dividend

$0.00

Beta (Volatility)

1.45 (Average)

Price

$16.29

Volume

402,565.759

Open

$15.98

Previous Close

$16.05

Daily Range

$15.88 - $16.27

52-Week Range

$12.12 - $35.34

Estimated Earnings Date

Aug 6, 2026

JANX News

SellAlert-Purple.png

Options Exercise: Janux Executive Sells 16,665 Shares for $501,000

Sara AppinoDec 4, 2025
Foolcom-Featured.png

Janux (JANX) R&D Soars Revenue Misses

Motley Fool Markets TeamAug 7, 2025
Person in a lab gazing into a microscope

Why Janux Therapeutics Crushed the Market Today

Eric VolkmanDec 4, 2024
Big fish eating little fish

Why Janux Therapeutics Stock Is Crushing It This Week

Keith SpeightsApr 12, 2024
Two people seated at a lab desk featuring a PC screen and microscope

Why Janux Therapeutics Stock Soared as the Market Sagged Today

Eric VolkmanApr 10, 2024
scientist holds up petri dish to the light

After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?

Alex CarchidiMar 2, 2024
dnaphoto

Why Janux Therapeutics Shares Rose 33.1% This Week

James HalleyOct 22, 2022

JANX: Motley Fool Moneyball Superscore

55

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Janux Therapeutics

Janux helps people with cancer by making smarter immune system treatments. Medicine stays inactive in healthy areas to prevent side effects. These drugs only wake up inside tumors to attack disease.

Fighting Cancer with Precision

  • JANX007: Clinical-stage therapy targeting prostate-specific membrane antigen (PSMA), a protein found on prostate cancer cells.
  • JANX008: Cancer drug targeting epidermal growth factor receptor (EGFR), which is a protein found in solid tumors.
  • JANX011: Autoimmune treatment using the Adaptive Immune Response Modulator (ARM) platform to clear disease-causing immune cells.
  • TRACIr Platform: Technology designed to create Tumor Activated Immunomodulators (TRACIr) that boost immune responses against tumors.

Where Is Janux Heading?

  • Entered a research collaboration with Merck in December 2020 to develop next-generation cancer therapies.
  • Announced the first patient dosed in the lead Merck collaboration program in August 2025.
  • Formed an exclusive license agreement with Bristol Myers Squibb in January 2026 to develop a tumor-activated therapeutic.
  • Initiated a Phase 1b expansion study for JANX007 in taxane-naive prostate cancer patients in May 2025.
  • Started Phase 1a expansion cohorts for JANX008 in multiple solid tumor indications in December 2025.

Smart Medicines and Selective Targeting

Janux uses proprietary masks to ensure its therapies only activate when they reach a tumor. This platform helps minimize cytokine release syndrome (CRS), a condition where the immune system overreacts. The company uses T cell engagers, which act as bridges between cancer and immune cells.

Key Financial Milestones

  • Revenue reached $7.9 million in Q4 2025, up from $0 the previous year.
  • Net income loss deepened to $31.9 million in Q4 2025, a 58% worsening year-over-year.
  • Free cash flow reached $54.6 million in Q4 2025, up from -$16.8 million in Q4 2024.
  • Operating income loss deepened to $42.4 million in Q4 2025, a 46.1% worsening from 2024.

Bottom Line

Janux has evolved from a research firm into a clinical-stage biotech company with multiple human trials. Its strategy focuses on solving the safety and duration issues of traditional immune therapies.

AI Generated • May 3, 2026

Industry

Biotechnology

Sector

Health Care

Employees

109

CEO

David Campbell, PhD

Website

www.januxrx.com

Headquarters

San Diego, CA 92037, US

JANX Financials

Key Financial Metrics (TTM)

Gross Margin

-80.84%

Operating Margin

-726.34%

Net Income Margin

-529.67%

Return on Equity

-11.85%

Return on Capital

-16.11%

Return on Assets

-11.13%

Earnings Yield

-11.48%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$978.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

60.98M

Volume

402.57K

Avg. Volume

1.09M

Financials (TTM)

Gross Profit

-$17.47M

Operating Income

-$156.98M

EBITDA

-$112.45M

Operating Cash Flow

-$77.55M

Capital Expenditure

-$945.00K

Free Cash Flow

-$78.49M

Cash & ST Invst.

$956.39M

Total Debt

$21.57M

Janux Therapeutics Performance Analysis

Janux Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,612,000136.8%
20232023-12-31USD 8,083,000-6.1%
20242024-12-31USD 10,588,00031.0%
20252025-12-31USD 10,000,000-5.6%
Janux Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31-21.2%
Q12026-03-31-52.6%
Janux Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.5291.9%
20232023-12-31USD -1.32-12.9%
20242024-12-31USD -1.28-3.1%
20252025-12-31USD -1.8342.8%
Janux Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-44.7%
Q32025-09-3029.1%
Q42025-12-31-30.8%
Q12026-03-3123.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$3.73M

N/A

Gross Profit

$3.26M

+113.0%

Gross Margin

87.44%

N/A

Market Cap

$978.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.98M

N/A

Employees

109

N/A

Net Income

-$24.36M

-3.6%

EBITDA

-$23.89M

-3.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$956.39M

-5.7%

Total Debt

$21.57M

-4.6%

Accounts Receivable

$42.46M

+660.3%

Inventory

$0.00

N/A

Long Term Debt

$19.10M

-8.2%

Short Term Debt

$2.47M

+36.5%

Return on Assets

-11.13%

N/A

Return on Invested Capital

-16.20%

N/A

Free Cash Flow

-$12.61M

+27.5%

Operating Cash Flow

-$12.34M

+27.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MAZEMaze Therapeutics, Inc.
$29.30+3.28%
BHVNBiohaven Ltd.
$15.50+4.31%
ZYMEZymeworks Inc.
$24.05+1.22%
ABCLAbCellera Biologics Inc.
$5.97+2.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$7.59+0.11%
NOKNokia
$10.65+0.06%
MARAMara Holdings
$12.12+0.04%
AALAmerican Airlines Group
$15.23+0.01%

Questions About JANX

What is the current price of Janux Therapeutics?

Janux Therapeutics is trading at $16.19 per share.

What is the 52-week range for Janux Therapeutics?

Over the past 52 weeks, Janux Therapeutics has traded between $12.12 and $35.34.

How much debt does Janux Therapeutics have?

As of the most recent reporting period, Janux Therapeutics reported total debt of $21.57M.

How much cash does Janux Therapeutics have on hand?

Janux Therapeutics reported $51.83M in cash and cash equivalents in its most recent financial results.

What is Janux Therapeutics’s dividend yield?

Janux Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services